Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials

被引：19
作者：
Cabibbo, Giuseppe [1 ]
Cucchetti, Alessandro [2 ,3 ,4 ]
Camma, Calogero [1 ]
Casadei-Gardini, Andrea [4 ]
Celsa, Ciro [1 ]
Rizzo, Giacomo Emanuele Maria [1 ]
Johnson, Philip [5 ]
Ercolani, Giorgio [2 ,3 ]
机构：
[1] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Sect Gastroenterol & Hepatol, PROMISE, Palermo, Italy
[2] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy
[3] Univ Bologna, Alma Mater Studiorum, Bologna, Italy
[4] Univ Modena, Dept Med & Surg Sci Children & Adults, Div Med Oncol, Policlin Modena Azienda Osped, Modena, Italy
[5] Univ Liverpool, Dept Mol & Clin Canc Med, Duncan Bldg,Daulby St, Liverpool, Merseyside, England
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 29期
关键词：
hepatocellular carcinoma; meta-regression; sorafenib; survival; systemic therapy; time to progression; RANDOMIZED CLINICAL-TRIALS; DOUBLE-BLIND; SURVIVAL; EFFICACY; THERAPY; CANCER; SAFETY;
D O I：
10.2217/fon-2019-0287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
引用
收藏
页码：3411 / 3422
页数：12
相关论文
共 41 条
  • [1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 54 - 63
  • [2] Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding:: A meta-analysis
    Bañares, R
    Albillos, A
    Rincón, D
    Alonso, S
    González, M
    Ruiz-del-Arbol, L
    Salcedo, M
    Molinero, LM
    [J]. HEPATOLOGY, 2002, 35 (03) : 609 - 615
  • [3] Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
    Bruix, Jordi
    Cheng, Ann-Lii
    Meinhardt, Gerold
    Nakajima, Keiko
    De Sanctis, Yoriko
    Llovet, Josep
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (05) : 999 - 1008
  • [4] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Bruix, Jordi
    Qin, Shukui
    Merle, Philippe
    Granito, Alessandro
    Huang, Yi-Hsiang
    Bodoky, Gyrogy
    Pracht, Marc
    Yokosuka, Osamu
    Rosmorduc, Olivier
    Breder, Valeriy
    Gerolami, Rene
    Masi, Gianluca
    Ross, Paul J.
    Song, Tianqiang
    Bronowicki, Jean-Pierre
    Ollivier-Hourmand, Isabelle
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Llovet, Josep M.
    Finn, Richard S.
    LeBerre, Marie-Aude
    Baumhauer, Annette
    Meinhardt, Gerold
    Han, Guohong
    [J]. LANCET, 2017, 389 (10064) : 56 - 66
  • [5] Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
    Cabibbo, Giuseppe
    Celsa, Ciro
    Calvaruso, Vincenza
    Petta, Salvatore
    Cacciola, Irene
    Cannavo, Maria Rita
    Madonia, Salvatore
    Rossi, Margherita
    Magro, Bianca
    Ini, Francesca
    Distefano, Marco
    Larocca, Licia
    Prestileo, Tullio
    Malizia, Giuseppe
    Bertino, Gaetano
    Benanti, Francesco
    Licata, Anna
    Scalisi, Ignazio
    Mazzola, Giovanni
    Di Rosolini, Maria Antonietta
    Alaimo, Giuseppe
    Averna, Alfonso
    Cartabellotta, Fabio
    Alessi, Nicola
    Guastella, Salvatore
    Russello, Maurizio
    Scifo, Gaetano
    Squadrito, Giovanni
    Raimondo, Giovanni
    Trevisani, Franco
    Craxi, Antonio
    Di Marco, Vito S.
    Camma, Calogero
    [J]. JOURNAL OF HEPATOLOGY, 2019, 71 (02) : 265 - 273
  • [6] Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
    Cabibbo, Giuseppe
    Celsa, Ciro
    Camma, Calogero
    Craxi, Antonio
    [J]. LIVER INTERNATIONAL, 2018, 38 (12) : 2108 - 2116
  • [7] A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma
    Cabibbo, Giuseppe
    Petta, Salvatore
    Barbara, Marco
    Missale, Gabriele
    Virdone, Roberto
    Caturelli, Eugenio
    Piscaglia, Fabio
    Morisco, Filomena
    Colecchia, Antonio
    Farinati, Fabio
    Giannini, Edoardo
    Trevisani, Franco
    Craxi, Antonio
    Colombo, Massimo
    Camma, Calogero
    [J]. LIVER INTERNATIONAL, 2017, 37 (08) : 1157 - 1166
  • [8] Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma
    Cabibbo, Giuseppe
    Petta, Salvatore
    Barbara, Marco
    Attardo, Simona
    Bucci, Laura
    Farinati, Fabio
    Giannini, Edoardo G.
    Negrini, Giulia
    Ciccarese, Francesca
    Rapaccini, Gian Lodovico
    Di Marco, Maria
    Caturelli, Eugenio
    Zoli, Marco
    Borzio, Franco
    Sacco, Rodolfo
    Virdone, Roberto
    Marra, Fabio
    Mega, Andrea
    Morisco, Filomena
    Benvegnu, Luisa
    Gasbarrini, Antonio
    Svegliati-Baroni, Gianluca
    Foschi, Francesco Giuseppe
    Olivani, Andrea
    Masotto, Alberto
    Nardone, Gerardo
    Colecchia, Antonio
    Persico, Marcello
    Craxi, Antonio
    Trevisani, Franco
    Camma, Calogero
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (01) : 65 - 71
  • [9] A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma
    Cabibbo, Giuseppe
    Enea, Marco
    Attanasio, Massimo
    Bruix, Jordi
    Craxi, Antonio
    Camma, Calogero
    [J]. HEPATOLOGY, 2010, 51 (04) : 1274 - 1283
  • [10] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han-Chong
    Gorbunova, Vera
    Eskens, Ferry A. L. M.
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El-Nowiem, Saied
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77
12345